What top creators are saying about Novo Nordisk(NVO)— Page 4
154 AI-extracted insights from 32 sources — podcasts, YouTube channels, and X/Twitter accounts.
Insights about Novo Nordisk (NVO) — Page 4 of 4
Showing insights 151–154 of 154.
Monday, June 23, 2025
The company canceled its partnership with HIMS, a move that HIMS's CEO stated was an attempt to 'strong-arm' them into compromising clinical standards.
Mentioned as being in a dispute with Hims & Hers Health, as Novo is reportedly upset that Hims is compounding weight-loss drugs, which violates the 'spirit of their agreement.'
Terminated its partnership with HIMS, raising concerns about the 'legality and safety' of HIMS's products. The stock fell ~5.5% on the news and is facing intense competition for its weight-loss drugs.
Portrayed negatively as a 'rent-seeking' business trying to protect its high-priced products (Wegovy at $1,349/month) by terminating its partnership with a low-cost disruptor, revealing a defensive posture and potential long-term vulnerability.
Monday, June 23, 2025
The company canceled its partnership with HIMS, a move that HIMS's CEO stated was an attempt to 'strong-arm' them into compromising clinical standards.
Mentioned as being in a dispute with Hims & Hers Health, as Novo is reportedly upset that Hims is compounding weight-loss drugs, which violates the 'spirit of their agreement.'
Terminated its partnership with HIMS, raising concerns about the 'legality and safety' of HIMS's products. The stock fell ~5.5% on the news and is facing intense competition for its weight-loss drugs.
Portrayed negatively as a 'rent-seeking' business trying to protect its high-priced products (Wegovy at $1,349/month) by terminating its partnership with a low-cost disruptor, revealing a defensive posture and potential long-term vulnerability.